Cure8 research brief
Researchers and clinicians are exploring fungi’s role in IBD beyond bacteria. For patients, seeing Candida in stool tests is usually a signal of microbiome disruption rather than proof of fungal infection that requires antifungal treatment.
Researchers studying the gut microbiome/mycobiome, gastroenterologists and IBD clinicians, and adult patients with IBD curious about stool fungal findings or microbiome-targeted therapies.
This narrative review synthesizes human and mechanistic studies on the gut mycobiome in IBD, focusing on Candida spp. The authors report heterogeneous, method-dependent fungal findings across studies and note that higher Candida relative abundance has been associated with active disease in some cohorts but not consistently.
Experimental data suggest fungal expansion, morphology, and strain-specific virulence can trigger inflammation in selected settings, while stool sequencing cannot determine viability, invasion, or causality.
The review highlights that interventions (antifungals, fecal microbiota transplantation, nutraceuticals) may alter microbial or inflammatory markers but have not shown consistent clinical benefit.
The authors recommend interpreting fecal Candida detection as a context-dependent signal of disrupted bacterial–fungal–immune interactions rather than proof of infection or a reason to treat with antifungals.
This brief is grounded in the article abstract and full-text extraction provided; it summarizes the authors' synthesis without evaluating individual study quality or unpublished data.
The article is a narrative review (43 sources) with heterogeneous study methods and mixed findings; stool sequencing cannot establish fungal viability or tissue invasion. Clinical trials showing consistent benefit from antifungals or other fungal-targeted interventions are lacking.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This pooled analysis compares multiple microbiota-directed therapies and suggests FMT, probiotics, and synbiotics may improve clinical remission in adults with IBD, with FMT also showing benefit for endoscopic remission....
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
The article reviews current and emerging IBD treatments and the biological reasons they may work — useful for patients wanting to understand treatment options and future directions. It highlights therapies beyond...
